Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer

被引:109
作者
Tentes, AAK [1 ]
Tripsiannis, G
Markakidis, SK
Karanikiotis, CN
Tzegas, G
Georgiadis, G
Avgidou, K
机构
[1] Didmotichn Gen Hosp, Dept Surg, Didmotichon 68300, Greece
[2] Democritus Univ Thrace, Stat Lab, Komotini, Greece
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2003年 / 29卷 / 01期
关键词
peritoneal cancer index; ovarian cancer;
D O I
10.1053/ejso.2002.1380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The peritoneal cancer index (PC[) has been used for the detailed evaluation of the peritoneal spread in tumors of gastrointestinal origin and has been found to be a prognostic indicator of survival. The aim of this study was the identification of the significance of the peritoneal cancer index in advanced ovarian cancer. Methods: From 1990 to 2001, 60 women, mean age 65 +/- 10.84 (41-86), were treated for advanced ovarian cancer. The performance status (Karnofsky performance scale), age, prior surgery score (PSS), peritoneal cancer index (PCI), tumor volume, tumor grade, residual tumor, the presence of ascites, treatment with adjuvant chemotherapy, histopathologic subtype and FIGO stage were retrospectively correlated to survival using univariate model of statistical analysis. Results: Hospital mortality and morbidity were 11.7 and 16.7% respectively. The recurrence rate was 23.3%. Overall 5-year survival rate was 41% and mean survival 63 +/- 8 months. The peritoneal cancer index was related to survival (P = 0.0253). The other favorable clinical prognostic indicators of survival were low grade and small volume tumors, treatment with adjuvant chemotherapy and complete cytoreductive surgery (P < 0.05). Conclusions: The peritoneal spread in advanced ovarian cancer can be assessed in detail using the peritoneal cancer index. It is a significant prognostic factor of survival and is useful in identifying subgroups. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:69 / 73
页数:5
相关论文
共 23 条
[1]   Natural history and prognosis of untreated stage I epithelial ovarian carcinoma [J].
Ahmed, FY ;
Wiltshaw, E ;
AHern, RP ;
Nicol, B ;
Shepherd, J ;
Blake, P ;
Fisher, C ;
Gore, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2968-2975
[2]  
ANSELL SM, 1993, GYNECOL ONCOL, V30, P215
[3]   Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma [J].
Begossi, G ;
Gonzalez-Moreno, S ;
Ortega-Perez, G ;
Fon, LJ ;
Sugarbaker, PH .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (01) :80-87
[4]   REPRODUCIBILITY AND PROGNOSTIC VALUE OF HISTOLOGIC TYPE AND GRADE IN EARLY EPITHELIAL OVARIAN-CANCER [J].
BERTELSEN, K ;
HOLUND, B ;
ANDERSEN, E .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1993, 3 (02) :72-79
[5]  
Berthet B, 1998, 8TH WORLD CONGRESS OF THE INTERNATIONAL GASTRO-SURGICAL CLUB, P899
[6]  
DESOUZA P, 1992, HEMATOL ONCOL CLIN N, V4, P761
[7]  
EISENKOP S, 1992, Gynecologic Oncology, V45, P97, DOI 10.1016/0090-8258(92)90581-3
[8]  
Friedlander ML, 1998, SEMIN ONCOL, V25, P305
[9]  
Jacquet P., 1996, J Exp Clin Cancer Res, V82, P359, DOI DOI 10.1007/978-1-4613-1247-5_23
[10]  
LEVIN L, 1993, ANN ONCOL, V4, P23